Phenylketonuria (PKU) Clinical Trials

Find Phenylketonuria (PKU) Clinical Trials Near You

The Impact of Frequency of Home Phenylalanine Measurements on Metabolic Control in a Population of Patients With Classic Phenylketonuria (FreqPHEncy) - a Single-center Randomized Cross-over Clinical Trial

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Recommendations regarding the frequency of phenylalanine level monitoring lack solid support from evidence derived from prospective randomized trials, including in the adult population with classic PKU. Current recommendations indicate that in adults (excluding the period of pregnancy planning and pregnancy itself), Phe levels should be assessed at least once a month or more frequently if additional indications exist. As part of this study, we plan to obtain, for the first time, high-quality data on the impact of Phe monitoring frequency on Phe control in adults. The primary objective of the study will be to assess the effect of the frequency (once a week versus once a month) of Phe level measurements on the metabolic control of phenylketonuria, as expressed by Phe concentration in DBS, in adult patients with the classic form of phenylketonuria.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Informed consent to participate in the study

• Male or female participants aged ≥18 and ≤65 years

• Clinical diagnosis of classic phenylketonuria (PKU) documented in the medical history by at least 2 measurements of blood phenylalanine concentration

• ≥600 μmol/l and a predicted PAH enzyme activity \<1% (GPV), requiring treatment with a low-protein diet supplemented with special low-phenylalanine amino acid mixtures

• Blood phenylalanine concentration in the range of 360-900 μmol/l during current therapy at the time of screening, and blood phenylalanine concentration in the range of 360-900 μmol/L during current treatment, based on the arithmetic mean of the last 3 Phe measurements from the participant's medical history (including the value from the screening)

• Ability and willingness, in the investigator's opinion, to comply with all requirements of the study.

Locations
Other Locations
Poland
Department of Diabetology, Internal Medicine, and Metabolic Diseases, Metabolic Diseases Clinic, University Hospital in Kraków
RECRUITING
Krakow
Contact Information
Primary
Michal Kania, MD, PhD
mich.kania@uj.edu.pl
+48124002950
Time Frame
Start Date: 2026-09-11
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 36
Treatments
Experimental: Sequence 1
Sequence 1 starts with intervention period 1 with DBS Phe measurements once a week for 24 weeks, followed by a 2-week wash-out period and intervention period 2 with DBS Phe measurements once a month for 24 weeks.
Experimental: Sequence 2
Sequence 2 starts with intervention period 1 with DBS Phe measurements once a month for 24 weeks, followed by a 2-week wash-out period and intervention period 2 with DBS Phe measurements once a week for 24 weeks.
Related Therapeutic Areas
Sponsors
Leads: Michał Kania
Collaborators: Polskie Towarzystwo Wrodzonych Was Metabolizmu, Jagiellonian University Medical College - Department and Clinic of Metabolic Diseases (Katedra i Klinika Chorób Metabolicznych UJ)

This content was sourced from clinicaltrials.gov